Oncogene:肌醇聚磷酸酯4-磷酸酶II型调控雄激素受体的活性

2018-10-07 AlexYang MedSci原创

晚期前列腺癌中AR的激活和转录重组总是与2个肿瘤抑制因子,INPP4B和PTEN的功能丧失同时发生,上述2个肿瘤抑制因子在人类和小鼠前列腺上皮中高表达。虽然AR信号通过PTEN的调控已经被多个研究组阐释,但是否INPP4B功能的丧失影响AR的活性仍旧不清楚。最近,有研究人员利用前列腺癌细胞系,展示了INPP4B能够调控AR转录活性和致瘤信号途径Akt和PKC。在前列腺癌患者群体中基因表达的分析表明

晚期前列腺癌中AR的激活和转录重组总是与2个肿瘤抑制因子,INPP4B和PTEN的功能丧失同时发生,上述2个肿瘤抑制因子在人类和小鼠前列腺上皮中高表达。虽然AR信号通过PTEN的调控已经被多个研究组阐释,但是否INPP4B功能的丧失影响AR的活性仍旧不清楚。

最近,有研究人员利用前列腺癌细胞系,展示了INPP4B能够调控AR转录活性和致瘤信号途径Akt和PKC。在前列腺癌患者群体中基因表达的分析表明了INPP4B的表达与AR mRNA水平和AR转录输出呈现负相关关系。研究人员通过使用Inpp4b-/-小鼠模型,阐释了INPP4B能够抑制Akt和PKC信号途径,并且在正常小鼠前列腺中调控AR转录活性。明显的是,PTEN蛋白水平和S380磷酸化水平在Inpp4b-/-和WT雄性小鼠中相同,表明了观察到的变化是由INPP4B功能的丧失引起。

最后,研究人员指出,他们的数据表明了INPP4B在正常前列腺中能够调节AR的活性,其功能的丧失在前列腺癌中能够导致AR依赖的转录。

原始出处:

Manqi Zhang, Egla Suarez, Judy L. Vasquez et al. Inositol polyphosphate 4-phosphatase type II regulation of androgen receptor activity. Oncogene. 18 Sep 2018.

本文系梅斯医学(MedSci)原创编译整理,转载需授权!

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2049097, encodeId=fe0d204909e8c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 19 10:21:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350540, encodeId=ac791350540da, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 09 01:21:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558131, encodeId=4db11558131da, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Oct 09 01:21:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596035, encodeId=c4871596035ac, content=<a href='/topic/show?id=7b24e386455' target=_blank style='color:#2F92EE;'>#磷酸酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73864, encryptionId=7b24e386455, topicName=磷酸酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=584e18318123, createdName=andy2093, createdTime=Tue Oct 09 01:21:00 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
    2019-05-19 cy0324
  2. [GetPortalCommentsPageByObjectIdResponse(id=2049097, encodeId=fe0d204909e8c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 19 10:21:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350540, encodeId=ac791350540da, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 09 01:21:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558131, encodeId=4db11558131da, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Oct 09 01:21:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596035, encodeId=c4871596035ac, content=<a href='/topic/show?id=7b24e386455' target=_blank style='color:#2F92EE;'>#磷酸酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73864, encryptionId=7b24e386455, topicName=磷酸酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=584e18318123, createdName=andy2093, createdTime=Tue Oct 09 01:21:00 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=2049097, encodeId=fe0d204909e8c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 19 10:21:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350540, encodeId=ac791350540da, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 09 01:21:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558131, encodeId=4db11558131da, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Oct 09 01:21:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596035, encodeId=c4871596035ac, content=<a href='/topic/show?id=7b24e386455' target=_blank style='color:#2F92EE;'>#磷酸酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73864, encryptionId=7b24e386455, topicName=磷酸酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=584e18318123, createdName=andy2093, createdTime=Tue Oct 09 01:21:00 CST 2018, time=2018-10-09, status=1, ipAttribution=)]
    2018-10-09 zsyan
  4. [GetPortalCommentsPageByObjectIdResponse(id=2049097, encodeId=fe0d204909e8c, content=<a href='/topic/show?id=4363e929ad' target=_blank style='color:#2F92EE;'>#Gene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=7929, encryptionId=4363e929ad, topicName=Gene)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=63a4277, createdName=cy0324, createdTime=Sun May 19 10:21:00 CST 2019, time=2019-05-19, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1350540, encodeId=ac791350540da, content=<a href='/topic/show?id=a7689869104' target=_blank style='color:#2F92EE;'>#雄激素受体#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=98691, encryptionId=a7689869104, topicName=雄激素受体)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Tue Oct 09 01:21:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1558131, encodeId=4db11558131da, content=<a href='/topic/show?id=2f1c13349e7' target=_blank style='color:#2F92EE;'>#Oncogene#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=23, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=13349, encryptionId=2f1c13349e7, topicName=Oncogene)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=154614942533, createdName=zsyan, createdTime=Tue Oct 09 01:21:00 CST 2018, time=2018-10-09, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1596035, encodeId=c4871596035ac, content=<a href='/topic/show?id=7b24e386455' target=_blank style='color:#2F92EE;'>#磷酸酶#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=34, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=73864, encryptionId=7b24e386455, topicName=磷酸酶)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=584e18318123, createdName=andy2093, createdTime=Tue Oct 09 01:21:00 CST 2018, time=2018-10-09, status=1, ipAttribution=)]

相关资讯

Prostate Cancer P D:化疗后转移去势难治性前列腺癌男性在恩杂鲁胺治疗期间,雄激素阻断治疗重要性分析

恩杂鲁胺能够显著的延长转移去势难治性前列腺癌(mCRPC)患者的生存时间。然而,在mCRPC患者中继续急性雄激素阻断治疗(ADT)方面还缺乏相关证据。最近,有研究人员分析了在进行了化疗的mCRPC患者中,在恩杂鲁胺治疗期间伴随ADT治疗的效果与影响。研究人员回顾性的分析了232名mCRPC患者的医疗记录,他们在化疗后接受了口服恩杂鲁胺治疗(160?mg每天)。时间地点分别为2014年到2016年之

Front Physiol:维生素C摄入和前列腺癌风险研究

维生素C是一种还原物质和自由基清除物质,在细胞内的质膜上具有抗氧化作用。基于这些特性,相关研究人员调查了维生素C在癌症发生率上的影响。但是基于大群体的与前列腺癌相关的研究很少,并且证据显示倾向于认为维生素C与前列腺癌没有相关性。尽管如此,许多之前的研究忽视了前列腺癌的恶化,以及筛选和组织检测,这也导致了倾向性相关性的存在。最近,有研究人员在加拿大蒙特利尔进行了基于大群体的研究。研究发现,日常摄入维

CLIN CANCER RES:肿瘤干细胞与巨噬细胞相互作用促进前列腺癌进展和耐药

肿瘤干细胞(CSC)有助于前列腺癌的进展和去势治疗(ADT)耐药。CSC依赖于其特定的肿瘤环境,包括肿瘤相关的巨噬细胞(TAM)。理解CSC和TAM之间的相互作用可能有助于抑制前列腺癌的进展和ADT耐药。CLIN CANER RES近期发表了一篇文章研究这一问题。

ANN ONCOL:MiCaP模型可以预测前列腺癌患者术后结局

目前需要可以预测前列腺癌(PC)预后的新分子生物标志物。ANN ONCOL近期发表了一篇文章,研究了一种新的4-miRNA预后比率模型在前列腺癌中的预后作用。

Clin Cancer Research:李振斐研究组及合作实验室揭示前列腺癌中雄激素代谢酶17βHSD2的功能及调节机制

国际学术期刊Clinical Cancer Research在线发表了中国科学院生物化学与细胞生物学研究所李振斐研究组的最新研究成果“Functional silencing of HSD17B2 in prostate cancer promotes disease progression”。

FDA认定rucaparib作为前列腺癌突破性疗法资格

Clovis Oncology公司10月2日宣布,Rubraca (rucaparib)用于单药治疗既往接受过抗雄激素受体疗法以及紫杉烷类化疗的BRCA1/2+成人转移性去势抵抗前列腺癌(mCRPC)已被FDA授予突破性疗法资格。rucaparib之前也被FDA授予过单药治疗特定晚期卵巢癌患者的突破性疗法资格,并且在2016年12月19日被FDA批准用于单药治疗既往接受过两种以上化疗的BRCA突变